Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer
Medicinal Chemistry Research · 02.11.2026
DOI: 10.1007/s00044-026-03633-3 ↗Kurz gefasst
Editorial in der Zeitschrift Medicinal Chemistry Research, online erschienen am 02.11.2026. Verfasst von Daniel Baecker. Beteiligte Einrichtung: Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195, Berlin, Germa…. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Freie Universität Berlin.
Abstract (Originalsprache)
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative tumors are the most common types of breast cancer. Mutation of ESR1 complicates their therapy. On September 04, 2026, camizestrant (Etcamah ® ) received approval for HR-positive and HER2-negative, locally advanced or metastatic breast cancer after detecting ESR1 mutation during medication with aromatase and CDK4/6 inhibitors. The mutation was identified through circulating tumor deoxyribonucleic acid, thus representing its first interventional use to guide a therapy switch as part of a clinical study. Camizestrant is a selective estrogen receptor degrader (SERD) and complete antagonist of the estrogen receptor. A dose of 75 mg is taken by mouth once daily concomitantly with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. In a drug regimen comprising an aromatase inhibitor along with a CDK4/6 inhibitor, a significant improvement in progression-free survival was achieved when the aromatase inhibitor was exchanged for camizestrant. This makes camizestrant a next-generation oral SERD for treating advanced breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195, Berlin, Germany. d.baecker@fu-berlin.de.
ORCID-Profile: Daniel Baecker
Förderung
- Freie Universität Berlin
Zitieren
APA
Baecker, D. (2026). Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer. Medicinal Chemistry Research. https://doi.org/10.1007/s00044-026-03633-3
Vancouver
Baecker D. Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer. Medicinal Chemistry Research. 2026. doi:10.1007/s00044-026-03633-3
BibTeX
@article{Baecker2026,
author = {Baecker, Daniel},
title = {Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer},
journal = {Medicinal Chemistry Research},
year = {2026},
doi = {10.1007/s00044-026-03633-3}
}
EUVIMED